Imaging and pharmacokinetics of 64Cu-DOTA-HB22.7 administered by intravenous, intraperitoneal, or subcutaneous injection to mice bearing non-hodgkin's lymphoma xenografts

Shiloh M. Martin, Robert T O'Donnell, David L. Kukis, Craig K. Abbey, Hayes McKnight, Julie Sutcliffe, Joseph Tuscano

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Purpose: The aim of the study is to compare the tumor-specific targeting, pharmacokinetics, and biodistribution of 64Cu- DOTA-HB22.7 when administered to xenograft-bearing mice intravenously (IV), intraperitoneally (IP), and subcutaneously (SQ). Procedures: Mice bearing human non-Hodgkin's lymphoma (NHL) xenografts were injected IV, IP, or SQ with 64Cu-DOTA-HB22.7. Xenograft targeting was evaluated by micro positron emission tomography (microPET) and confirmed by organ biodistribution studies. Blood measurements of 64Cu were performed to determine the pharmacokinetics and clearance of 64Cu-DOTA-HB22.7. Results: 64Cu-DOTA-HB22.7 demonstrated equivalent tumor targeting within 24-48 h, regardless of the route of administration. Organ biodistribution confirmed tumor-specific targeting. Blood pharmacokinetics demonstrated that 64Cu-DOTA-HB22.7 accessed the bloodstream after IP and SQ administration to a similar degree as IV administration, albeit at a slower rate. Conclusions: These findings establish 64Cu-DOTA-HB22.7 as a potential radioimmunotherapeutic and/or NHL-specific imaging agent. These findings provide evidence that IP and SQ administration can achieve results equivalent to IV administration and may lead to more efficient, reproducible treatment plans for antibody-based therapeutics.

Original languageEnglish (US)
Pages (from-to)79-87
Number of pages9
JournalMolecular Imaging and Biology
Volume11
Issue number2
DOIs
StatePublished - 2009

Fingerprint

Subcutaneous Injections
Intraperitoneal Injections
Heterografts
Intravenous Injections
Non-Hodgkin's Lymphoma
Pharmacokinetics
Neoplasms
Positron-Emission Tomography
Antibodies
Therapeutics

Keywords

  • Cu
  • CD22
  • HB22.7
  • Non-Hodgkin's lymphoma
  • PET

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

@article{caf1bf9529a04828a95cd50aadb98ef8,
title = "Imaging and pharmacokinetics of 64Cu-DOTA-HB22.7 administered by intravenous, intraperitoneal, or subcutaneous injection to mice bearing non-hodgkin's lymphoma xenografts",
abstract = "Purpose: The aim of the study is to compare the tumor-specific targeting, pharmacokinetics, and biodistribution of 64Cu- DOTA-HB22.7 when administered to xenograft-bearing mice intravenously (IV), intraperitoneally (IP), and subcutaneously (SQ). Procedures: Mice bearing human non-Hodgkin's lymphoma (NHL) xenografts were injected IV, IP, or SQ with 64Cu-DOTA-HB22.7. Xenograft targeting was evaluated by micro positron emission tomography (microPET) and confirmed by organ biodistribution studies. Blood measurements of 64Cu were performed to determine the pharmacokinetics and clearance of 64Cu-DOTA-HB22.7. Results: 64Cu-DOTA-HB22.7 demonstrated equivalent tumor targeting within 24-48 h, regardless of the route of administration. Organ biodistribution confirmed tumor-specific targeting. Blood pharmacokinetics demonstrated that 64Cu-DOTA-HB22.7 accessed the bloodstream after IP and SQ administration to a similar degree as IV administration, albeit at a slower rate. Conclusions: These findings establish 64Cu-DOTA-HB22.7 as a potential radioimmunotherapeutic and/or NHL-specific imaging agent. These findings provide evidence that IP and SQ administration can achieve results equivalent to IV administration and may lead to more efficient, reproducible treatment plans for antibody-based therapeutics.",
keywords = "Cu, CD22, HB22.7, Non-Hodgkin's lymphoma, PET",
author = "Martin, {Shiloh M.} and O'Donnell, {Robert T} and Kukis, {David L.} and Abbey, {Craig K.} and Hayes McKnight and Julie Sutcliffe and Joseph Tuscano",
year = "2009",
doi = "10.1007/s11307-008-0148-1",
language = "English (US)",
volume = "11",
pages = "79--87",
journal = "Molecular Imaging and Biology",
issn = "1536-1632",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - Imaging and pharmacokinetics of 64Cu-DOTA-HB22.7 administered by intravenous, intraperitoneal, or subcutaneous injection to mice bearing non-hodgkin's lymphoma xenografts

AU - Martin, Shiloh M.

AU - O'Donnell, Robert T

AU - Kukis, David L.

AU - Abbey, Craig K.

AU - McKnight, Hayes

AU - Sutcliffe, Julie

AU - Tuscano, Joseph

PY - 2009

Y1 - 2009

N2 - Purpose: The aim of the study is to compare the tumor-specific targeting, pharmacokinetics, and biodistribution of 64Cu- DOTA-HB22.7 when administered to xenograft-bearing mice intravenously (IV), intraperitoneally (IP), and subcutaneously (SQ). Procedures: Mice bearing human non-Hodgkin's lymphoma (NHL) xenografts were injected IV, IP, or SQ with 64Cu-DOTA-HB22.7. Xenograft targeting was evaluated by micro positron emission tomography (microPET) and confirmed by organ biodistribution studies. Blood measurements of 64Cu were performed to determine the pharmacokinetics and clearance of 64Cu-DOTA-HB22.7. Results: 64Cu-DOTA-HB22.7 demonstrated equivalent tumor targeting within 24-48 h, regardless of the route of administration. Organ biodistribution confirmed tumor-specific targeting. Blood pharmacokinetics demonstrated that 64Cu-DOTA-HB22.7 accessed the bloodstream after IP and SQ administration to a similar degree as IV administration, albeit at a slower rate. Conclusions: These findings establish 64Cu-DOTA-HB22.7 as a potential radioimmunotherapeutic and/or NHL-specific imaging agent. These findings provide evidence that IP and SQ administration can achieve results equivalent to IV administration and may lead to more efficient, reproducible treatment plans for antibody-based therapeutics.

AB - Purpose: The aim of the study is to compare the tumor-specific targeting, pharmacokinetics, and biodistribution of 64Cu- DOTA-HB22.7 when administered to xenograft-bearing mice intravenously (IV), intraperitoneally (IP), and subcutaneously (SQ). Procedures: Mice bearing human non-Hodgkin's lymphoma (NHL) xenografts were injected IV, IP, or SQ with 64Cu-DOTA-HB22.7. Xenograft targeting was evaluated by micro positron emission tomography (microPET) and confirmed by organ biodistribution studies. Blood measurements of 64Cu were performed to determine the pharmacokinetics and clearance of 64Cu-DOTA-HB22.7. Results: 64Cu-DOTA-HB22.7 demonstrated equivalent tumor targeting within 24-48 h, regardless of the route of administration. Organ biodistribution confirmed tumor-specific targeting. Blood pharmacokinetics demonstrated that 64Cu-DOTA-HB22.7 accessed the bloodstream after IP and SQ administration to a similar degree as IV administration, albeit at a slower rate. Conclusions: These findings establish 64Cu-DOTA-HB22.7 as a potential radioimmunotherapeutic and/or NHL-specific imaging agent. These findings provide evidence that IP and SQ administration can achieve results equivalent to IV administration and may lead to more efficient, reproducible treatment plans for antibody-based therapeutics.

KW - Cu

KW - CD22

KW - HB22.7

KW - Non-Hodgkin's lymphoma

KW - PET

UR - http://www.scopus.com/inward/record.url?scp=60049099141&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=60049099141&partnerID=8YFLogxK

U2 - 10.1007/s11307-008-0148-1

DO - 10.1007/s11307-008-0148-1

M3 - Article

C2 - 18949521

AN - SCOPUS:60049099141

VL - 11

SP - 79

EP - 87

JO - Molecular Imaging and Biology

JF - Molecular Imaging and Biology

SN - 1536-1632

IS - 2

ER -